Lamivudine/tenofovir

From WikiProjectMed
Jump to navigation Jump to search
Lamivudine/tenofovir
Lamivudine and tenofovir disoproxil.svg
Combination of
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Names
Trade namesCimduo, Temixys
Clinical data
Main usesPrevent and treat HIV/AIDS[1][2]
Side effectsHeadache, pain, diarrhea, rash, depression, liver problems, kidney problems, pancreatitis, osteoporosis, lactic acidosis, immune reconstitution syndrome[1][1]
Routes of
use
By mouth
External links
AHFS/Drugs.comMonograph
MedlinePlusa618039
Legal
License data
Legal status

Lamivudine/tenofovir disoproxil (3TC/TDF), sold under the brand name Cimduo among others, is a combination medication used to prevent and treat HIV/AIDS.[1][2] It is taken by mouth.[1] It is used together with other medications in people weighing more than 35 kilograms (77 lb).[1]

Common side effects include headache, pain, diarrhea, rash, and depression.[1] Other side effects may include liver problems, kidney problems, pancreatitis, osteoporosis, lactic acidosis, and immune reconstitution syndrome.[1] In those who are also infected with hepatitis B, stopping use may worsen outcomes.[1] It contains lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) both reverse transcriptase inhibitors.[1]

The combination was approved for medical use in the United States in 2018.[1] It is also approved in a number of countries in Europe.[1] The lamivudine component was first approved in 1995.[4] It was added to the World Health Organization's List of Essential Medicines in 2021.[5][2] It is available in some areas as a generic medication.[4] In the United States it costs about 1,100 USD per month as of 2023.[6] Though the individual components cost about 140 USD per month if purchased separately.[7] It appears to work as well as emtricitabine/tenofovir but is less expensive.[4][8]

Medical uses

Dosage

It is taken as one pill once per day.[1] Each pill contains 300 mg of lamivudine and 300 mg of tenofovir.[1]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Archived from the original on 15 February 2020. Retrieved 26 March 2020.
  2. 2.0 2.1 2.2 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 27 March 2023. Retrieved 19 October 2023.
  3. "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Archived from the original on 14 February 2022. Retrieved 13 February 2022.
  4. 4.0 4.1 4.2 Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
  5. World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  6. "Cimduo". Retrieved 19 October 2023.
  7. Rosenberg, Tina. "H.I.V. Drugs Cost $75 in Africa, $39,000 in the U.S. Does It Matter?". New York Times. Archived from the original on 9 February 2023. Retrieved 19 October 2023.
  8. "HIV Prevention: What the TDF/3TC? The rationale and the evidence for TDF/3TC in PrEP". www.who.int. Archived from the original on 20 October 2023. Retrieved 19 October 2023.

External links

Identifiers: